CCS
PJP icon

Crosspoint Capital Strategies’s Invesco Pharmaceuticals ETF PJP Stock Holding History

Crosspoint Capital Strategies’s Portfolio PJP Stock Details PJP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1,040
Closed -$69K – 629
2015
Q4 		$69K Buy
+1,040
New +$73.7K 0.02% 397

Other funds holding PJP

LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
PAM
Peak Asset Management Louisville, Colorado $680M AUM 22.27% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
SCM
Summit Capital Management Seattle, Washington $221M AUM 4.14% 1-Year Est. Return

Crosspoint Capital Strategies's PJP Position: Q1 2016 in Review

Crosspoint Capital Strategies sold out of Invesco Pharmaceuticals ETF (PJP) in Q1 2016, closing a stake of 1,040 shares — an estimated $69K sold.

Crosspoint Capital Strategies first reported a position in PJP in Q4 2015 and held it in 1 quarter. The position peaked at $69K in Q4 2015. 93 funds tracked by Wall St. Rank hold PJP as of Q1 2016.

  • Crosspoint Capital Strategies reported no remaining Invesco Pharmaceuticals ETF position as of Q1 2016 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 1,040 Invesco Pharmaceuticals ETF shares in Q1 2016, an estimated $69K.
  • Crosspoint Capital Strategies first reported a position in Invesco Pharmaceuticals ETF in Q4 2015 and held it in 1 quarter.
  • Crosspoint Capital Strategies's Invesco Pharmaceuticals ETF position peaked at $69K in Q4 2015.
  • 93 funds tracked by Wall St. Rank held Invesco Pharmaceuticals ETF as of Q1 2016.

Based on Crosspoint Capital Strategies's 13F filing for Q1 2016, filed 16 May 2016.